Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

PHASE2CompletedINTERVENTIONAL
Enrollment

444

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

December 10, 2018

Study Completion Date

December 10, 2018

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

Multivalent

Pneumococcal conjugate vaccine

BIOLOGICAL

Prevnar 13

Pneumococcal conjugate vaccine

BIOLOGICAL

PPSV23

Pneumococcal polysaccharide vaccine

OTHER

Saline

Placebo

Trial Locations (14)

29414

Medical Research South, LLC, Charleston

30281

Clinical Research Atlanta, Stockbridge

32720

Avail Clinical Research, LLC, DeLand

33134

Clinical Research of South Florida, Coral Gables

33143

Qps-Mra, Llc, South Miami

67207

Heartland Research Associates, LLC, Wichita

73112

Lynn Health Science Institute, Oklahoma City

77375

Martin Diagnostic Clinic, Tomball

78229

Clinical Trials of Texas, Inc., San Antonio

78705

Benchmark Research, Austin

84020

J. Lewis Research Inc. / Foothill Family Clinic Draper, Draper

84095

J. Lewis Research, Inc. - Jordan River Family Medicine, South Jordan

92801

Anaheim Clinical Trials, LLC, Anaheim

96814

East-West Medical Research Institute, Honolulu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03313037 - Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age | Biotech Hunter | Biotech Hunter